Marina Biotech this week announced that a microRNA inhibitor modified with the company's proprietary conformationally restricted nucleotide technology could trigger dose-dependent, in vivo de-repression of target genes.
Separately, the company said that it has signed a deal securing up to $15 million in equity capital from an institutional investor.
The CRN technology essentially comprises nucleotide analogs to which the C2' and C4' carbon bonds of the ribose ring are linked.